8-K: Aptose Biosciences Faces Nasdaq Delisting Notice Over Share Issuance to Hanmi Pharmaceutical

Aptose Biosciences received a deficiency letter from Nasdaq for issuing shares to Hanmi Pharmaceutical without prior shareholder approval, potentially leading to delisting.

Summary

• Aptose Biosciences received a deficiency letter from Nasdaq on February 29, 2024, stating that the company violated listing rule 5635(d).
• The violation occurred due to the issuance of shares to Hanmi Pharmaceutical, which exceeded 20% of outstanding shares and was at a discount to the market price on January 25, 2024.
• This issuance was completed without prior shareholder approval, which is required under Nasdaq rules.
• The deficiency letter does not immediately affect the trading of Aptose's shares on Nasdaq, which will continue under the symbol APTO.
• Aptose's shares also trade on the Toronto Stock Exchange (TSX) under the symbol APS, and this listing is unaffected by the Nasdaq issue.
• Aptose has 45 calendar days, until April 14, 2024, to submit a plan to regain compliance with Nasdaq listing rules.
• If Nasdaq accepts the plan, Aptose may receive an extension of up to 180 calendar days to demonstrate compliance.
• Aptose believes the Hanmi transaction was compliant but will work with Nasdaq to resolve the issue, though there is no guarantee of regaining compliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the Nasdaq deficiency notice, raising concerns about the company's compliance and future listing status.

Positives

• The company's shares continue to trade on Nasdaq and the TSX despite the deficiency notice.
• Aptose has been given 45 days to submit a plan to regain compliance, with a potential extension of up to 180 days.

Negatives

• Aptose violated Nasdaq listing rule 5635(d) by issuing shares to Hanmi Pharmaceutical without shareholder approval.
• The share issuance exceeded 20% of outstanding shares and was at a discount to the market price.
• There is no guarantee that Aptose will be able to regain compliance with Nasdaq listing rules.

Risks

• There is a risk of delisting from Nasdaq if Aptose fails to regain compliance with listing rules.
• The company's share price could be negatively impacted by the uncertainty surrounding its Nasdaq listing.
• The company may need to take significant actions to regain compliance, which could be costly and time-consuming.

Future Outlook

Aptose intends to work with Nasdaq to resolve the compliance issue and will consider available options to regain compliance, but there is no assurance of success.

Management Comments

• Aptose believes that the Hanmi Transaction was completed in accordance with the Nasdaq Listing Rules.
• Aptose respects Nasdaq's query and intends to work with Nasdaq to resolve Nasdaq's concerns.

Industry Context

This situation highlights the importance of adhering to exchange listing rules, particularly regarding share issuances, and the potential consequences of non-compliance for publicly traded companies.

Comparison to Industry Standards

• Many companies have faced similar delisting notices for non-compliance with exchange rules, such as failing to maintain minimum share price or not meeting financial requirements.
• Companies like Delcath Systems and Titan Pharmaceuticals have previously faced similar issues with Nasdaq, highlighting the importance of strict adherence to listing rules.
• The specific rule violation, 5635(d), is a common issue for companies that issue a significant number of shares without shareholder approval, which is a standard requirement for most exchanges.

Stakeholder Impact

• Shareholders may experience a decline in share value due to the uncertainty surrounding the Nasdaq listing.
• The company's reputation may be negatively impacted by the delisting notice.
• Employees may be concerned about the company's future prospects.

Next Steps

• Aptose must submit a plan to Nasdaq by April 14, 2024, to regain compliance.
• Aptose will work with Nasdaq to resolve the compliance issue and consider available options.

Key Dates

Keywords

Nasdaq, delisting, compliance, share issuance, Hanmi Pharmaceutical, listing rules, Aptose Biosciences, shareholder approval